Skip to Main Content


Skip Nav Destination

Current Issue: Mid-January 2022

Highlights from the 2021 ASH Annual Meeting

Hematologists from around the world gathered in person and virtually for the latest scientific insights and valuable networking opportunities.



Blood Advances is a Different Vein

Study Characterizes Mutational Landscape and CHIP-Related Mutations in Hematologic Malignancies

ASH Updates Clinical Practice Guidelines on Post-Discharge Anticoagulation Use in Patients With COVID-19

Literature Scan

 Researchers Identify Specific Genetic Abnormalities Predictive of Myeloid and Lymphoid Malignancies

On Location

Daratumumab-KRd Quadruplet Therapy, AHCT, and Consolidation Therapy Lead to High MRD Negativity in Newly Diagnosed Myeloma

Isatuximab Plus RVd Improves MRD Negativity Rates in Patients With Newly Diagnosed Multiple Myeloma

ctDNA: A Noninvasive Tool for Diagnosis and Outcome Prediction in CNS Lymphomas

Venetoclax Plus FLAG-IDA Shows Promising Responses in Newly Diagnosed AML

Sabatolimab Combined With Hypomethylating Agents Appears Safe and Effective in MDS and AML

Rusfertide Leads to Hematocrit Control in Patients With Polycythemia Vera

Emicizumab Improves Bleeding Prophylaxis in Patients With Acquired Hemophilia A

Cytopenia Associated With Increased Risk of Cancer Death, Particularly in Black Patients

Fitusiran Significantly Reduced Bleeding in Hemophilia A and B With Inhibitors

Access to Transfusions Plays Crucial Role in Hospice Decision-Making

Azacitidine With Venetoclax and Magrolimab Shows Promise for Newly Diagnosed, High-Risk AML

Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise in Relapsed/Refractory B-Cell NHL

ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma

Evaluating the Safety and Efficacy of Rilzabrutinib in Relapsed/Refractory ITP

No Increased Risk of Deep Vein Thrombosis After COVID-19 Vaccination

GRIFFIN: Daratumumab Combination Maintains Deep Durable Response in Transplant-Eligible Myeloma

Could Liso-cel Become a New Second-Line Standard for Relapsed/Refractory LBCL?

Multi-Omic Analysis Provides Insights into TP53-Mediated Evolution of Malignancies

APPs Are Limited in Prescribing Chemotherapy Based on Oncology Setting, Geography

IPSS That Incorporates Gene Mutations Offers Better Risk Stratification for MDS

High-Dose Methotrexate Does Not Reduce CNS Relapse in Aggressive B-cell Lymphoma

Researchers Report Positive Early Data for Etavopivat in Sickle Cell Disease

Fitusiran Reduces Bleeding Risk in Patients With Hemophilia A or B Without Inhibitors

Comparing Tisa-Cel to Standard of Care in  Relapsed/Refractory Aggressive B-Cell NHL

Adding Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL

Close Modal

or Create an Account

Close Modal
Close Modal